Template:Smallpox Treatment: Difference between revisions

(Created page with "*IMMEDIATE NOTIFICATION OF PUBLIC HEALTH AUTHORITIES *Vaccine administered up to 3 days post-exposure was effective in preventing infection as well as lessening the severity o...")
 
(→‎Active Disease: added clinical window for vaccine efficacy (before appearance of derm lesions). Helpful for cases with unknown last known exposure.)
Line 8: Line 8:
*Vaccinia Vaccine within the first 72hrs can decrease total disease severity and within 7 days may decrease symptoms
*Vaccinia Vaccine within the first 72hrs can decrease total disease severity and within 7 days may decrease symptoms
*Supportive care and wound care for open lesions
*Supportive care and wound care for open lesions
*Vaccination is not efficacious once the patient has developed rash

Revision as of 19:30, 11 September 2021

  • IMMEDIATE NOTIFICATION OF PUBLIC HEALTH AUTHORITIES
  • Vaccine administered up to 3 days post-exposure was effective in preventing infection as well as lessening the severity of the disease if infection occurred [1]

Postexposure Prophylaxis

  • Vaccinia Vaccine (administer within 72hrs of exposure)

Active Disease

  • Vaccinia Vaccine within the first 72hrs can decrease total disease severity and within 7 days may decrease symptoms
  • Supportive care and wound care for open lesions
  • Vaccination is not efficacious once the patient has developed rash
  1. Kman NE, Nelson RN. Infectious agents of bioterrorism: a review for emergency physicians. Emerg Med Clin North Am. 2008 May;26(2):517-47